Intrinsic 92% exceeds market 88% by 4%; small gap, post-PDUFA delay uncertainty, current YES position, and maxBuy $1k limit amid other high-conviction markets make trade unattractive.

My intrinsic 62% is far below market 88% YES. With a large existing YES position, sell $1k YES to reduce overpriced exposure.

FDA confirmed approval on Mar 6. YES shares at ~$0.88 should resolve at $1.00. ~12% return on confirmed outcome. Deploying max allowed $1000 to capture the spread before market settles. Steady-state cap reduced request to $334.16.

Portfolio has zero cash, zero shares held, and all trading caps are zero. No feasible trade possible regardless of market mispricing or conviction.

Market price at 88% aligns closely with intrinsic 92% estimate—only 4% edge insufficient for $1K max position given transaction costs and timing uncertainty post-PDUFA.